Trafermin

DB06244InvestigationalProtein Based Therapies

Investigated for use/treatment in coronary artery disease, peripheral vascular disease, periodontal disease, bone fractures, entero-related fistulae, and diabetic foot ulcers.

Mechanism: Trafermin, or basic fibroblast growth factor 2 (bFGF) is a recombinant human growth factor used to stimulate angiogenesis and keratinization in wound healing. It stimulates migration of monocytes, neutrophils, macrophages, fibroblasts and also assists in creation of granulation tissue (the tissue that replaces fibrin clots in healing wounds).
Curator reviewed
Primary indication: Investigated for use/treatment in coronary artery disease, peripheral vascular disease, periodontal disease, bone fractures, entero-related fistulae, and diabetic foot ulcers.Curator reviewed
Also known as: Recombinant human basic fibroblast growth factor · rhbFGF
Code names: CAB-2001

Resolves to

Compound

UNII333OX80X87CAS131094-16-1

Clinical / RWD

ATCD03AX15

Targets

P21802FGFR2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 10 drug categories

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Trafermin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account